Medicare doesn’t cover weight loss drugs because a 2003 federal law specifically bans it. When Congress created the Medicare Part D prescription drug benefit, it excluded several categories of medications, including any “agents when used for anorexia, weight loss, or weight gain.” That exclusion remains in effect today, which means roughly 40% of Medicare beneficiaries who have obesity cannot get these medications covered, even as drugs like semaglutide have shown dramatic results in clinical trials.
The 2003 Law Behind the Exclusion
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created Part D, the program that helps cover outpatient prescription drugs for Medicare enrollees. But Congress built in a list of drug categories that Part D plans are not allowed to cover. Weight loss drugs landed on that list alongside medications used for cosmetic purposes, cough and cold remedies, over-the-counter drugs, and prescription vitamins.
The exclusions weren’t invented from scratch. Congress borrowed them from an existing list of drug categories that state Medicaid programs were already allowed to exclude. At the time, the weight loss drugs available were modest in effectiveness and sometimes carried serious safety concerns. The exclusion was partly a cost-control measure and partly a reflection of how policymakers viewed obesity treatment in 2003: more as a lifestyle issue than a medical one. Two decades later, the science has shifted dramatically, but the law hasn’t.
The Same Drug, Two Different Rules
This is where the policy gets especially frustrating for patients. Semaglutide, the active ingredient in both Ozempic and Wegovy, is the same compound. Ozempic is FDA-approved for type 2 diabetes. Wegovy is approved for weight management and, more recently, for reducing cardiovascular risk. Medicare Part D covers Ozempic for diabetes without issue. But if the same molecule is prescribed specifically for weight loss, the 2003 exclusion kicks in and Part D cannot pay for it.
The distinction has nothing to do with chemistry or effectiveness. It comes down to the indication written on the prescription. If a doctor prescribes semaglutide to manage blood sugar, it’s covered. If the same doctor prescribes it to treat obesity in a patient without diabetes, it’s excluded by statute. This creates an odd incentive structure where Medicare will pay to treat many consequences of obesity (joint replacements, heart procedures, diabetes management) but not the obesity itself.
The Cardiovascular Loophole
A narrow opening appeared in 2024. The FDA approved Wegovy for a new use: reducing the risk of heart attack and stroke in people with established cardiovascular disease who also have obesity or are overweight. Because this indication targets cardiovascular risk rather than weight loss per se, it falls outside the 2003 exclusion.
After that FDA approval, the Centers for Medicare and Medicaid Services issued guidance confirming that Part D plans can add Wegovy to their formularies for this specific use. The catch is that eligibility is limited to people who already have established cardiovascular disease, meaning a prior heart attack, prior stroke, or peripheral arterial disease. A Medicare enrollee with obesity alone, even severe obesity, still cannot get coverage for the drug. Plans also aren’t required to cover it; they’re simply permitted to.
Why Congress Hasn’t Changed the Law
Legislation called the Treat and Reduce Obesity Act has been introduced in multiple sessions of Congress. It would lift the Part D exclusion and allow coverage of anti-obesity medications for beneficiaries with a BMI of 30 or higher, or a BMI of 27 to 30 with a weight-related chronic condition. The bill has attracted bipartisan support but has not passed, largely because of cost concerns.
The Congressional Budget Office estimated that authorizing Medicare to cover anti-obesity medications starting in 2026 would increase federal spending by about $35 billion over nine years, from 2026 to 2034. Direct drug costs would rise from $1.6 billion in the first year to $7.1 billion by 2034. Health savings from fewer hospitalizations, surgeries, and chronic disease complications would offset only a fraction of that: less than $50 million in savings the first year, growing to about $1 billion by 2034. Over the full nine-year window, improved health would reduce other healthcare spending by roughly $3.4 billion, against $38.8 billion in drug costs.
That math makes lawmakers cautious. Even though obesity drives enormous Medicare spending on diabetes, heart disease, and joint problems (rising disease prevalence from obesity has accounted for up to 17% of Medicare’s growth in diabetes expenditures alone), the upfront cost of covering these medications for millions of beneficiaries is steep. The drugs currently cost over $1,000 per month at list price, and the eligible population is huge.
What This Means for Medicare Enrollees Now
If you’re on Medicare and want access to a GLP-1 drug for weight loss, your options are limited. You can get coverage for Ozempic if you have type 2 diabetes, since that’s a covered indication. You may be able to get Wegovy covered if you have both obesity and established cardiovascular disease, though your specific Part D plan would need to include it on its formulary. For weight loss alone, you’d need to pay out of pocket, which typically runs $1,000 or more per month without insurance.
Medicare Advantage plans, the private alternatives to traditional Medicare, face the same statutory restriction. The 2003 exclusion applies to all Part D coverage regardless of whether it’s delivered through original Medicare or a Medicare Advantage plan. Some Medicare Advantage plans offer supplemental benefits for things like gym memberships or nutrition counseling, but covering excluded drug categories requires an act of Congress.
The gap between what medicine can now do for obesity and what Medicare is allowed to pay for remains one of the more significant disconnects in American healthcare policy. The law was written when the best weight loss drugs produced modest results. The drugs have changed; the statute hasn’t.